Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2026)

Alnylam Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $218.0 million for Q1 2026.

• Quarterly Operating Leases fell 5.23% year-over-year to $218.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.0 million (down 5.23% YoY) and the FY2025 annual result came in at $225.1 million, down 1.94% from the prior year.
• Operating Leases was $218.0 million for Q1 2026 at Alnylam Pharmaceuticals, down from $225.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $277.4 million in Q1 2022 and bottomed at $218.0 million in Q1 2026.
• A 5-year average of $243.8 million and a median of $239.4 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases fell 8.32% — and 2025, when it declined 1.94%.
• Alnylam Pharmaceuticals' Operating Leases stood at $261.3 million in 2022, then decreased by 6.98% to $243.1 million in 2023, then slipped by 5.58% to $229.5 million in 2024, then decreased by 1.94% to $225.1 million in 2025, then dropped by 3.14% to $218.0 million in 2026.
• Business Quant data shows ALNY's Operating Leases at $218.0 million in Q1 2026, $225.1 million in Q4 2025, and $223.4 million in Q3 2025.